Relating to collecting a tax from all manufacturers and distributors of opioid drugs
Summary
HB3406 would create a new West Virginia excise tax on opioid drugs and certain other Schedule II opioid substances sold to licensed pharmacies in the state. The tax would be calculated as one cent per 100 pills, multiplied by the number of overdose deaths in West Virginia from the most recent year available, with the Department of Health providing the overdose-death data each year and the Tax Commissioner setting the annual amount to be collected.
The bill directs pharmacies to collect and remit the tax to the Tax Commissioner, but prohibits manufacturers, distributors, pharmacies, or any other party from passing the tax on to patients. Revenue would be deposited into the Ryan Brown Addiction Prevention and Recovery Fund to support addiction prevention and recovery programs. The bill also authorizes the Tax Commissioner to adopt rules to administer the tax collection process.
Impact
HB3406 would add a new article to the West Virginia Code creating a targeted excise tax on opioid manufacturers, distributors, and pharmacy sales of Schedule II opioid drugs. It would affect pharmaceutical supply chains, licensed pharmacies, and the Tax Commissioner by imposing new reporting, collection, and remittance duties, while also tying the tax rate to annual overdose mortality data from the Department of Health. The bill would not directly tax patients, and it would channel the resulting revenue into an existing state fund for addiction prevention and recovery.
Sentiment
Based on the bill text and available context, the measure appears to be framed as a public-health and opioid-response funding proposal rather than a broad tax increase. There is no recorded committee debate or vote history in the provided materials, so no formal support or opposition is documented here. The stated purpose suggests an intent to direct opioid-related revenue toward treatment and prevention efforts, which typically appeals to advocates for addiction services and public health funding.
Contention
The main points of potential contention are the imposition of a new excise tax on opioid manufacturers, distributors, and pharmacies, and the unusual formula that scales the tax to the number of overdose deaths in the state. Opponents could argue that the tax may increase compliance burdens for pharmacies and drug distributors or indirectly affect drug pricing and access, even though the bill prohibits passing the cost on to patients. Supporters are likely to emphasize that the tax is narrowly targeted at opioid sales and earmarked for addiction prevention and recovery, but no specific stakeholder positions are provided in the available record.